COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu
Trial record 39 of 98 for:    Primary Sclerosing Cholangitis

Safety and Tolerability of Cilofexor in Participants With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04060147
Recruitment Status : Recruiting
First Posted : August 16, 2019
Last Update Posted : November 6, 2020
Information provided by (Responsible Party):
Gilead Sciences

Brief Summary:
The primary objective of this study is to assess the safety and tolerability of escalating doses of cilofexor in participants with primary sclerosing cholangitis (PSC) and compensated cirrhosis.

Condition or disease Intervention/treatment Phase
Primary Sclerosing Cholangitis Compensated Cirrhosis Drug: CILO Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Proof-of-Concept, Open-Label Study Evaluating the Safety and Tolerability of Cilofexor in Subjects With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
Actual Study Start Date : October 17, 2019
Estimated Primary Completion Date : December 2021
Estimated Study Completion Date : December 2021

Arm Intervention/treatment
Experimental: CILO 30 mg
Participants will receive escalating doses of CILO 30 mg, 60 mg, and 100 mg.
Drug: CILO
Tablets administered orally once daily
Other Names:
  • Cilofexor
  • GS-9674

Primary Outcome Measures :
  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events [ Time Frame: First dose date up to Week 12 plus 30 days ]
  2. Percentage of Participants Experiencing Laboratory Abnormalities [ Time Frame: First dose date up to Week 12 plus 30 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of large duct PSC based on cholangiogram (magnetic resonance cholangiopancreatography [MRCP], endoscopic retrograde cholangiopancreatography [ERCP], or percutaneous transhepatic cholangiogram [PTC])
  • Individuals have evidence of cirrhosis based on historical liver biopsy, abdominal imaging (MRI, CT, or Ultrasound), or a screening FibroScan®, ELF™, or FibroTest®.
  • Individual has the following laboratory parameters at the Screening visit, as determined by the central laboratory:

    • Estimated glomerular filtration rate (eGFR) > 60 mL/min, as calculated by the Cockcroft-Gault equation
    • ALT ≤ 5 x ULN
    • Total Bilirubin ≤ 1.5 x ULN, except in confirmed cases of Gilbert's syndrome
    • INR ≤ 1.4, unless due to therapeutic anticoagulation
    • Platelet count ≥ 100,000/μL
    • Negative anti-mitochondrial antibody

Exclusion Criteria:

  • Current or prior history of any of the following

    • Decompensated liver disease, including ascites, hepatic encephalopathy (HE), or variceal hemorrhage
    • Liver transplantation
    • Cholangiocarcinoma or hepatocellular carcinoma (HCC).
  • Model for End-stage Liver Disease (MELD) score > 12 at Screening, unless due to an alternate etiology such as therapeutic anticoagulation
  • Child-Pugh (CP) score > 6 at Screening, unless due to an alternative etiology such as Gilbert's syndrome or therapeutic anticoagulation
  • Current moderate to severely active inflammatory bowel disease (IBD) in the opinion of the investigator

Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04060147

Layout table for location contacts
Contact: Gilead Clinical Study Information Center 1-833-445-3230 ext GILEAD-0

Layout table for location information
United States, Arizona
Arizona Liver Health Recruiting
Chandler, Arizona, United States, 85224
United States, California
California Liver Research Institute Recruiting
Pasadena, California, United States, 91105
United States, Florida
Schiff Center for Liver Diseases/University of Miami Recruiting
Miami, Florida, United States, 33136
United States, Georgia
Piedmont Atlanta Hospital Recruiting
Atlanta, Georgia, United States, 30309
United States, Indiana
Indiana University Health University Hospital Recruiting
Indianapolis, Indiana, United States, 46202
United States, Louisiana
Louisiana Research Center, LLC Recruiting
Shreveport, Louisiana, United States, 71105
United States, Minnesota
Minnesota Gastroenterology, PA Recruiting
Maplewood, Minnesota, United States, 55117
United States, New York
Northwell Health Center for Liver Diseases and Transplantation Recruiting
Manhasset, New York, United States, 11030
United States, Texas
The Liver Institute at Methodist Dallas Medical Center Recruiting
Dallas, Texas, United States, 75203
United States, Virginia
University of Virginia Medical Center Recruiting
Charlottesville, Virginia, United States, 22908
Bon Secours Richmond Community Hospital, Inc. d/b/a Bon Secours Liver Institute of Richmond Recruiting
Richmond, Virginia, United States, 23226
VCU Clinical Research Services Unit (CRSU) [Patient Site Address] Recruiting
Richmond, Virginia, United States, 23298
United States, Washington
University of Washington at Harborview Medical Center Recruiting
Seattle, Washington, United States, 98104
Liver Institute Northwest Recruiting
Seattle, Washington, United States, 98105
Sponsors and Collaborators
Gilead Sciences
Layout table for investigator information
Study Director: Gilead Study Director Gilead Sciences
Layout table for additonal information
Responsible Party: Gilead Sciences Identifier: NCT04060147    
Other Study ID Numbers: GS-US-428-5443
First Posted: August 16, 2019    Key Record Dates
Last Update Posted: November 6, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Liver Cirrhosis
Cholangitis, Sclerosing
Pathologic Processes
Liver Diseases
Digestive System Diseases
Bile Duct Diseases
Biliary Tract Diseases